Reata Pharmaceuticals (NASDAQ: RETA)
Some price data may be temporarily unavailable.
Reata Pharmaceuticals Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Reata Pharmaceuticals Company Info
In an industry in which many biotech companies focus only on diseases that affect huge numbers of people, Reata provides some diversification with its focus on orphan conditions.
News & Analysis
Could This Stock Be the Next Biotech Buyout?
A buyout deal recently pushed Reata Pharmaceuticals stock 53% higher in a single trading session, leading investors to wonder who's next.
3 Stocks That Already Doubled in 2023 and Could Keep Climbing
The gains these stocks notched in the first few months of the year could be the beginning of a much longer bull run.
3 Supercharged Stocks Near 52-Week Highs That Could Keep Climbing
The high-flyers have soared to new heights and further gains could be up ahead.
Why Reata Pharmaceuticals Stock Skyrocketed This Week
A major regulatory approval lit a fire underneath Reata's shares this week.
The Nasdaq Is Rebounding: 2 Supercharged Growth Stocks to Buy in February
These two growth stocks might deliver enormous gains for shareholders this month.
Why Reata Pharmaceuticals Stock Is Soaring Today
Investors are cheering the company's third-quarter update.
Why Reata Pharmaceuticals Stock Got Absolutely Crushed on Thursday
The biopharmaceutical company got some potentially devastating news from regulators.
Why Reata Pharmaceuticals Nose-Dived on Monday
The FDA has raised concerns about one of the company's key pipeline candidates in advance of a crucial meeting.
Valuation
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.